Executive Summary
Shenzhen Root Technology Co., Ltd. has filed a Petition challenging U.S. Patent No. 11,413,380 held by Chiaro Technology Ltd. The challenge centers on obviousness (Section 103), arguing that the claimed features of the breast pump are combinations of existing prior art references like Chang, Weber, and Guthrie.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in SHENZHEN ROOT TECHNOLOGY CO., LTD. et al. vs Chiaro Technology Ltd. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
SHENZHEN RONGLIDA TECHNOLOGY CO. LTD. d/b/a ShutterLightvsPathway IP LLC
The PTAB instituted the IPR challenge against Pathway IP LLC's '729 patent, finding a reasonable likelihood of success on obviousness grounds. The Petitioner argues that Claim 1 is obvious over Naghi and Dine by combining their respective features to create an optimized webcam illumination device.
Valve CorporationvsImmersion Corporation
Valve Corporation successfully petitioned to institute IPR against Immersion Corporation's patent (9,116,546), asserting that the haptic feedback claims are anticipated or obvious in view of prior art. The Board found a reasonable likelihood of success on Claim 1 based on Rosenberg.
Lenovo (United States) Inc. et al.vsIntellectual Ventures II
The Board found that U.S. Patent No. 7,325,140 B2 is unpatentable due to obviousness over prior art references. Specifically, the combination of Neufeld and Syvanne renders claims 11 and 12 obvious, while other combinations involving IPMI render multiple claims invalid.
Apple Inc.vsCarbyne Biometrics, LLC
Apple Inc.'s IPR challenge against Carbyne Biometrics was instituted by the PTAB, focusing on obviousness over combinations of prior art references like Stone, Hoyos, and Varghese. The Board found that the petitioner demonstrated a reasonable likelihood of unpatentability, allowing the case to proceed to trial.
Dexcom, Inc.vsAbbott Diabetes Care Inc.
Dexcom successfully petitioned to institute an IPR against Abbott Diabetes Care Inc.'s glucose monitoring patent (11298056). The Board found a reasonable likelihood of prevailing on grounds of obviousness (103) for claims 13 and 29.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.